CTOs on the Move

St Charles Parish Hospital

www.stch.net

 
St Charles Parish Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Luling, LA. To find more information about St Charles Parish Hospital, please visit www.stch.net
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million
  • www.stch.net
  • 1057 Paul Maillard Rd
    Luling, LA USA 70070-4349
  • Phone: 985.785.3662

Executives

Name Title Contact Details

Similar Companies

MMI

MMI is a Crystal Springs, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Supermed Inc

Supermed Inc is a Ormond Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radiant Health

Radiant Health is a functional medicine practice that focuses on empowering and inspiring women to reclaim their health by addressing the root cause of symptoms or disease and creating personalized lifestyle plans to achieve vitality and wellness.

University HealthSystem Consortium

UHC, based in Oak Brook, Ill., and representing 0.7 of the academic medical centers in the United States, is an alliance of 84 academic medical centers and 80 associate members.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic